J.P. Morgan Chase
Robbie Huffines, Co-head of Healthcare Investment Banking

Robbie Huffines – joined J.P. Morgan in 1992 and is currently co-head of the global healthcare investment banking group. Mr. Huffines is primarily focused on medical device, pharmaceutical, and biotechnology clients. Mr. Huffines has advised numerous healthcare companies on strategic transactions, including: Merck’s acquisition of Schering Plough (pending), Celgene’s acquisition of Pharmion, Kinetic Concept’s acquisition of LifeCell, Amgen’s sale of Amgen K.K. to Takeda, Guidant’s sale to Boston Scientific and Abbott, Bristol-Myers Squibb’s divestitures of Medical Imaging, Zimmer and Mead Johnson’s adult nutrition business, Guidant’s acquisition of CardioThoracic Systems and Cook (withdrawn); Sofamor Danek’s sale to Medtronic; Oratec’s sale to Smith & Nephew; Johnson & Johnson’s acquisitions of Mitek, Cordis, and Neutrogena.

Mr. Huffines’ equity offering experience includes offerings for Celgene, Medco Health Solutions, Kinetic Concepts, Zimmer, Guidant, Sofamor Danek, Oratec, Volcano, and Medtronic. Fixed income transaction experience includes offerings for Johnson & Johnson, Guidant, Baxter, and many pharmaceutical companies. Prior to joining J.P. Morgan, Mr. Huffines worked at Alex Brown & Sons, specializing in equity financings and advisory assignments for emerging growth companies.

Mr. Huffines has an M.B.A. from the University of Virginia, where he received the faculty award for academic excellence. He has a B.A. from the University of North Carolina, where he majored in English and Economics. Mr. Huffines is married and has four children. His volunteer work include The Brookings/Gates Global Health Innovative Financing Advisory Group, the Student Sponsor Partnership, and serving as a board member of the Spence School.